

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

PROPOSED ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY

This announcement is made pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) in relation to the proposed adoption of the new memorandum and articles of association (the “**New M&A**”) of Innovent Biologics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”).

The directors (the “**Directors**”) of the board (the “**Board**”) of the Company proposes to amend certain provisions of its existing Memorandum and Articles of Association (the “**Existing M&A**”) by way of adoption of the New M&A to (i) update and bring the Existing M&A in line with the relevant amendments made to the Listing Rules in respect of the electronic dissemination of corporate communications by listed issuers which came into effect from December 31, 2023; and (ii) make other consequential and housekeeping amendments.

The proposed adoption of the New M&A is subject to the approval of the shareholders of the Company (the “**Shareholders**”) by way of a special resolution at the forthcoming annual general meeting of the Company to be held on June 21, 2024 (the “**AGM**”) and if approved by the Shareholders, will become effective upon the approval by the Shareholders at the AGM.

A circular containing, among others, details of the proposed adoption of the New M&A and a notice convening the AGM will be despatched to the Shareholders in due course.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China,
March 20, 2024

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Dr. Kaixian Chen, Mr. Gary Zieziula and Dr. Shun Lu as Independent Non-executive Directors.